ISRCTN94465562 https://doi.org/10.1186/ISRCTN94465562

Nasogastric and intravenous erythromycin as prokinetic in intensive care patients: a randomised controlled study

Submission date 12/09/2003	**Recruitment status** No longer recruiting	[ ] Prospectively registered [ ] Protocol
Registration date 12/09/2003	**Overall study status** Completed	[ ] Statistical analysis plan [ ] Results
Last Edited 31/03/2020	**Condition category** Signs and Symptoms	[ ] Individual participant data [ ] Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr A Guha

Contact details
Anaesthesia
University Hospital Aintree
Longmoor Lane
Fazakerley
Liverpool
United Kingdom
L9 7AL
+44 (0)151 529 5152 / 5153
abc@email.com

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
N0025107242

Study information

Scientific Title
Nasogastric and intravenous erythromycin as prokinetic in intensive care patients: a randomised controlled study

Study objectives
Erythromycin's effect on gastric emptying in intensive care

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration

Study design
Randomised controlled trial

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Hospital

Study type(s)
Treatment

Participant information sheet

Health condition(s) or problem(s) studied
Signs and Symptoms: Gastric emptying

Interventions
A 5 ml sample of blood will be taken for measuring baseline paracetamol content. 1.5 g of soluble paracetamol will be administered to them through their nasogastric tube.
They will then be randomised to receive 250 g of either nasogastric or intravenous erythromycin. Further blood samples (5 ml each time) will be taken at 15, 30, 45, 60, 120, 180 and 240 min after giving paracetamol. These samples will then be sent to the laboratory for assay. After obtaining the data, these will be analysed for statistical significance.

Intervention Type
Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)
Erythromycin

Primary outcome measure
Not provided at time of registration

Secondary outcome measures
Not provided at time of registration

Overall study start date
01/01/2002

Completion date
01/07/2003

Eligibility

Key inclusion criteria
Intensive Care patients who will be recruited into the study if they exhibit a failure to absorb nasogastric feed.

Participant type(s)
Patient

Age group
Not Specified

Sex
Not Specified

Target number of participants
Not provided at time of registration

Key exclusion criteria
Not provided at time of registration

Date of first enrolment
01/01/2002

Date of final enrolment
01/07/2003

Locations

Countries of recruitment
England

United Kingdom

Study participating centre
University Hospital Aintree
Liverpool
United Kingdom
L9 7AL

Sponsor information

Organisation
Department of Health (UK)

Sponsor details
Richmond House
79 Whitehall
London
United Kingdom
SW1A 2NL

Sponsor type
Government

Website
http://www.doh.gov.uk

Funder(s)

Funder type
Hospital/treatment centre

Funder Name
Aintree Hospitals NHS Trust (UK)

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration